Although microglia have been implicated in nerve injury-induced neuropathic pain, the manner by which injured sensory neurons engage microglia remains unclear. We found that peripheral nerve injury induced de novo expression of colony-stimulating factor 1 (CSF1) in injured sensory neurons. CSF1 was transported to the spinal cord, where it targeted the microglial CSF1 receptor (CSF1R). Cre-mediated sensory neuron deletion of Csf1 completely prevented nerve injury-induced mechanical hypersensitivity and reduced microglial activation and proliferation. In contrast, intrathecal injection of CSF1 induced mechanical hypersensitivity and microglial proliferation. Nerve injury also upregulated CSF1 in motoneurons, where it was required for ventral horn microglial activation and proliferation. Downstream of CSF1R, we found that the microglial membrane adaptor protein DAP12 was required for both nerve injury-and intrathecal CSF1-induced upregulation of pain-related microglial genes and the ensuing pain, but not for microglial proliferation. Thus, both CSF1 and DAP12 are potential targets for the pharmacotherapy of neuropathic pain.
a r t I C l e S Neuropathic pain is a severe chronic pain condition that is characterized by ongoing mechanical hypersensitivity, where normally innocuous stimuli provoke intense pain 1, 2 . Given that traditional pharmacotherapies are largely ineffective against neuropathic pain 3 , the search continues for mechanism(s) by which nerve damage triggers pain. There is now considerable consensus that nerve damage alters pain transmission circuitry in the spinal cord dorsal horn 2 and that microglia, the tissue-resident macrophages in the CNS 4, 5 , are important contributors to this process [6] [7] [8] [9] . What underlies the activation of microglia, however, is still unclear. Notably, although activation of microglia was readily demonstrated after damage to the peripheral branch of the primary sensory neuron, microglia appeared to be unresponsive to transection of the central branch, namely the dorsal root 10 (Fig. 1a) . Thus, injured sensory neurons in dorsal root ganglia (DRG) must release a signal that communicates with and activates spinal cord microglia 1 .
Although a host of studies have sought sensory neuron-derived factors, it is still unclear how injured neurons initiate microglia activation. For example, fractalkine (CX3CL1), a chemokine that is cleaved from the membrane of sensory neurons after peripheral nerve injury 11 , requires cathepsin S (CatS), a protease released by already activated microglia 8 . Thus, fractalkine may contribute to the maintenance of, but cannot be the initiating signal for, microglia activation. Although the chemokines CCL2 and CCL21 have been reported to be induced in sensory neurons after nerve injury 12, 13 , CCR2, the receptor for CCL2, is not expressed in microglia 14 , and deletion of CCL21 has no effect on nerve injury-induced microglia activation or proliferation 13 . Neuregulin-1 (NRG-1) has also been implicated, but NRG-1 is not induced in sensory neurons after nerve injury 15 . Another view holds that ATP released after nerve injury binds to the microglial P2X4 purinergic receptor to initiate microglia activation 6, 16 . However, nerve injury-induced microglia activation is intact in P2X4 knockout mice 17 , and the source of ATP after nerve injury that binds the receptor has never been unequivocally identified 6 .
In addition to being activated, the microglia population expands after nerve injury 18 . Whether this expansion results from proliferation of local microglia or from infiltration of circulating monocytes is unclear. As both resident microglia and infiltrating monocytes express common markers, addressing the relative contribution of resident and infiltrating cells has been difficult. Using a model in which healthy bone marrow is transplanted into lethally irradiated recipients, a previous study concluded that circulating monocytes infiltrate into the CNS and contribute to the expansion of the microglia population 19 . On the other hand, using chimeric mice generated by parabiosis, another group concluded that the microglia expansion in the facial nucleus after VIIth (facial) nerve injury or in the spinal cord in an ALS mouse model derives exclusively from self-renewal of resident microglia 20 . Regardless of the source of the proliferation, neither the identity nor the cellular origin of the factor(s) by which injured neurons trigger microglia proliferation in vivo is known. a r t I C l e S To address these questions, we performed RNA-Seq and recorded a significant induction of CSF1 (namely, macrophage colony stimulating factor, MCSF) in the injured DRG. The nerve injury-induced upregulation of CSF1 occurred not only in injured DRG sensory neurons, but also in ventral horn motoneurons. Using Cre-mediated selective deletion of Csf1 from sensory neurons, we found that sensory neuron-derived CSF1 was required for the development of the neuropathic pain phenotype, as well as for microglia proliferation in the dorsal horn. Finally, we identified a critical downstream pathway in microglia that includes the membrane adaptor protein DAP12 in the generation of nerve injury and CSF1-induced neuropathic pain. However, nerve injury-and CSF1-induced microglial proliferation were DAP12 independent.
RESULTS

De novo induction of CSF1 in injured sensory neurons
To identify the genes that are upregulated in DRG and dorsal horn after nerve injury and the signals through which injured sensory neurons interact with microglia to produce pain, we first performed an RNA-Seq analysis after nerve injury ( Fig. 1a) . Many studies have reported transcriptional changes after nerve injury, but few examined both DRG and spinal cord and most were performed using microarray 21, 22 . We found a marked upregulation of Csf1 in the ipsilateral DRG and of Csf1r in the ipsilateral dorsal cord after nerve injury ( Supplementary Table 1 ). This finding is particularly important, as CSF1 is an essential factor added to culture medium to expand microglia in vitro 23 , and CSF1R is required in vivo for microglia development 24 . In fact, Csf1r is among the earliest genes expressed in microglia progenitors in yolk sac during microglia development 24, 25 .
Notably, the expression of IL-34, another CSF1R ligand 26 , did not change ( Supplementary Table 1 ). Quantitative RT-PCR (qRT-PCR) confirmed our finding that Csf1, but not Il-34, was induced in the DRG (Fig. 1b,c) , and that Csf1r was induced in the dorsal spinal cord ( Fig. 1d ) after nerve injury.
Subsequent in situ hybridization for Csf1 mRNA ( Fig. 2a ) and immunostaining for CSF1 protein (Fig. 2b) revealed that CSF1 was induced in DRG neurons that coexpressed ATF3, a marker of cells with damaged peripheral axons 27 . In fact, 1 d after nerve injury, all CSF1+ DRG neurons coexpressed ATF3 and ~80% of ATF3+ neurons coexpressed CSF1 ( Fig. 2b and Supplementary Fig. 1 ). The CSF1 induction occurred in both small-and large-diameter DRG neurons ( Fig. 2b ) within 18 h of the nerve injury and persisted for at least 3 weeks ( Supplementary Fig. 1 ). As we could not detect CSF1 in DRG neurons in the absence of injury ( Fig. 2b) , we conclude that nerve injury induces de novo CSF1 expression in the injured sensory neurons. We observed some CSF1 immunoreactivity in satellite cells of the DRG, but there was no change after nerve injury ( Fig. 2b) . a r t I C l e S CSF1 is transported to the spinal cord after nerve injury To determine whether sensory neuron-derived de novo CSF1 is transported to the spinal cord, we ligated the L4 and L5 dorsal roots (between the DRG and spinal cord; Fig. 1a ) after peripheral nerve injury and found accumulation of CSF1 at the ligatures ( Fig. 2c) .
Coexpression in DRG neurons and at the ligature site of CSF1 and NPY ( Supplementary Fig. 2a,b ), a peptide that is upregulated in injured sensory neurons 28 , confirmed the intra-axonal transport of CSF1.
In spinal cord, CSF1R is expressed only in microglia Next, using a CSF1R-GFP reporter mouse 29 and immunostaining for CSF1R, we found that CSF1R is expressed exclusively in spinal cord microglia and is indeed upregulated after nerve injury ( Fig. 2d and Supplementary Fig. 2c-f ). The fact that we did not observe a corresponding CSF1 increase in the dorsal horn suggests that CSF1 is rapidly released after its transport to the cord.
CSF1 is necessary and sufficient for microglia activation
To investigate the functional relevance of CSF1 upregulation in injured sensory neurons, we deleted Csf1 selectively from sensory neurons ( Fig. 3a,b ) by crossing a floxed Csf1 mouse (Csf1 fl/fl ) 30 with an Advillin-Cre (Adv-Cre) mouse in which Cre recombinase is only expressed in DRG sensory neurons 31 . Neither the morphology nor the density of spinal cord microglia contralateral to the nerve injury differed from that of wild-type mice ( Fig. 3c,d) , indicating that microglial development is not compromised in these mice. However, nerve injury-induced microglia activation in the ipsilateral dorsal horn, as demonstrated by increased Iba1 expression, was substantially reduced in these mice (Fig. 3c,d and Supplementary Fig. 3a) , even though the ATF3 induction in the injured sensory neurons was preserved ( Fig. 3b) . To test whether CSF1 by itself triggers microglial activation in vivo, we injected CSF1 intrathecally, once per day for 3 d and observed a marked activation of dorsal horn microglia, which manifested as enhanced Iba1 expression ( Fig. 3e and Supplementary Fig. 3b ). Together, these results suggest that CSF1 induction in injured sensory neurons is necessary and that CSF1 by itself is sufficient for nerve injury-induced microglia activation in the spinal cord dorsal horn.
CSF1 is necessary and sufficient for neuropathic pain
Next we asked whether sensory neuron-derived CSF1 also contributes to the neuropathic pain produced by nerve injury. Adv-Cre-mediated Csf1 deletion from sensory neurons completely prevented nerve injury-induced mechanical hypersensitivity, the hallmark of neuropathic pain 32 ( Fig. 4a and Supplementary Fig. 4a ).
In these mutant mice, body weight ( Supplementary Fig. 4b ), motor activity ( Supplementary Fig. 4c ), response to acute noxious heat stimulation ( Supplementary Fig. 4d,e ), hindpaw formalin (inflammation)-induced nocifensive behaviors ( Supplementary  Fig. 4f) , and numbers and neurochemical subpopulations of DRG neurons ( Supplementary Fig. 4g ,h) did not differ from wild-type mice. Consistent with a sufficiency of the CSF1 contribution to the neuropathic pain phenotype, intrathecal injection of CSF1 provoked substantial mechanical hypersensitivity in both wild-type animals ( Fig. 4b ) and in the mice in which Csf1 was deleted from DRG neurons ( Fig. 4c) . We also recorded morphological changes in dorsal horn microglia 2 h after intrathecal CSF1 ( Supplementary Fig. 5a ), as well as a small, but substantial, increase in Iba1 expression ( Supplementary Fig. 5b ). Consistent with these findings, the microglia inhibitor minocycline prevented the hypersensitivity produced by intrathecal CSF1 (Supplementary Fig. 5c ). Notably, although npg a r t I C l e S the P2X4 receptor is considered to be critical to the hypersensitivity following nerve injury 6 , intrathecal CSF1-induced mechanical hypersensitivity persisted in P2X4 knockout mice ( Fig. 4d) .
Finally, intrathecal CSF1 substantially upregulated several microglial genes ( Fig. 4f) , including Itgam (encoding CD11b), Cx3cr1, Bdnf (encoding brain-derived neurotrophic factor) and Ctss (encoding CatS). Many of these genes have been implicated in the development of neuropathic pain 8, 33 . Notably, the same microglia genes were upregulated in the dorsal cord 1 d after nerve injury ( Fig. 4e) . We conclude that de novo induction of CSF1 in injured sensory neurons triggers the expression of neuropathic pain-relevant microglial genes in the dorsal spinal cord, as well as the ensuing neuropathic pain condition.
DAP12 mediates microglial gene upregulation and pain
We next addressed the signal transduction pathway downstream of the microglial CSF1R. Our RNA-Seq analysis of the dorsal spinal cord ipsilateral to the nerve injury revealed a substantial upregulation of Tyrobp, the gene that encodes DAP12 ( Supplementary  Table 1 ). We focused on DAP12 as it is central to adult microglial functionality 5, 34 and is induced in microglia in the XIIth nucleus after hypoglossal nerve injury 35 . qRT-PCR showed that the Tyrobp induction was substantial within 1 d of injury ( Fig. 5a) and lasted for at least 7 d ( Supplementary Fig. 6a ). Intrathecal CSF1 also induced Tyrobp (Fig. 5b) , and, notably, Tyrobp deletion 36 completely prevented nerve injury and intrathecal CSF1-induced mechanical hypersensitivity ( Fig. 5c,d) , as well as the microglial gene upregulation ( Fig. 5e,f) , without affecting the de novo induction of CSF1 in sensory neurons (Supplementary Fig. 6b ). The mild hypersensitivity induced by CSF1 in the Tyrobp −/− mice ( Fig. 5d ) was comparable to that produced by phosphate-buffered saline (PBS) vehicle in wildtype mice (Fig. 4b) . Motor activity and response to acute noxious heat stimulation in the Tyrobp −/− mice did not differ from those of wild-type mice (Supplementary Fig. 6c-e ). We conclude that DAP12 lies downstream of CSF1R and is necessary for the CSF1-CSFR1triggered upregulation of pain-related microglial genes and of the consequent neuropathic pain condition. Notably, DAP12 is also required for hypoglossal nerve injury-induced expression of proinflammatory cytokines, including M1-phenotype markers 35 . Finally, in the rat, we found that DAP12 mechanisms also contribute to ongoing neuropathic pain. Autotomy (self-mutilation of a denervated limb) is presumed to arise from a persistent pain comparable to phantom limb pain. We found that basal levels of spinal cord Tyrobp mRNA were substantially higher in a strain of rats with high autotomy (HA) npg a r t I C l e S scores 37 than Tyrobp levels in rats that rarely develop this condition (low autotomy, LA). These Tyrobp differences were present both before and after nerve injury (Supplementary Fig. 7 ).
Nerve injury induces microglia self-renewal in spinal cord
In addition to establishing the neuropathic pain condition, peripheral nerve injury expands the spinal cord microglia population. Whether this expansion results from the infiltration of circulating monocytes or by self-renewal from local microglia remains controversial. Despite the comparable gene profile of microglia and monocytes, some genes (Csf1r and Cx3cr1) are expressed at higher levels in microglia; others (Trem1 and Trem3) are expressed exclusively in monocytes 38 . Our RNA-Seq analysis showed that, although the microglia-enriched genes were upregulated, the monocyte-specific genes remained undetectable after nerve injury ( Supplementary Table 1 ). We confirmed these RNA-Seq findings by qRT-PCR (Supplementary Fig. 8 ) and conclude, in agreement with a previous study 20 , that monocytes do not substantially infiltrate the spinal cord after nerve injury. Rather, microglia expansion after nerve injury involves self-renewal of resident microglia.
CSF1 is necessary and sufficient for microglia self-renewal
We next asked whether the de novo expression of CSF1 in injured sensory neurons is also required for nerve injury-induced microglia self-renewal in vivo. We first confirmed a previous report 18 that nerve injury triggers dorsal horn microglia proliferation, as demonstrated by incorporation of the thymidine analog BrdU into CSF1R-expressing microglia (Fig. 6a) . All dorsal horn BrdU+ cells expressed CSF1R 3 d after nerve injury ( Fig. 6a) , indicating that these proliferating cells originate from resident microglia, that is, the proliferation reflects microglial self-renewal. Note that the microglia proliferation occurred after the CSF1 was induced. We detected no microglia proliferation in the dorsal horn at 1 d post injury (Fig. 6b) , when CSF1 induction a r t I C l e S in sensory neurons is readily observed (Figs. 1b and 2a,b) . Notably, Adv-Cre-mediated deletion of Csf1 from DRG neurons largely eliminated the nerve injury-induced dorsal horn microglia proliferation ( Fig. 6c and Supplementary Fig. 9a ). Finally, intrathecal injection of CSF1 also induced microglia proliferation in the dorsal horn ( Fig. 6e and Supplementary Fig. 9c ) comparable to that provoked by nerve injury (Fig. 6a,b) . We conclude that sensory neuron-derived CSF1 is necessary and that CSF1 by itself is sufficient for microglia proliferation/self-renewal in the dorsal horn.
DAP12 is not required for microglia proliferation in vivo
Given that DAP12 is required for CSF1-induced proliferation of bone marrow-derived macrophages in vitro 39 and that it lies downstream of spinal cord microglial CSF1R in regulating pain-related microglial gene expression in vivo (Fig. 5e,f) , we expected that DAP12 also mediates microglia proliferation in vivo. To our surprise, however, Tyrobp deletion altered neither nerve injury nor intrathecal CSF1-induced dorsal horn microglial proliferation (Fig. 6d,e and Supplementary Fig. 9b,d) . Thus, although nerve injury-and CSF1-induced microglia gene induction and the consequent neuropathic pain condition are DAP12 dependent, nerve injury-and CSF1-induced microglia proliferation/self-renewal involves a DAP12independent pathway.
CSF1 is induced in injured motoneurons
As the sciatic nerve contains sensory and motor axons, its transection damages both DRG sensory neurons and ventral horn motoneurons 27 (Fig. 1a) . As for sensory neurons, we observed marked CSF1 induction in axotomized (ATF3 expressing) motoneurons (Fig. 7a,b) . The motoneuronal CSF1 induction occurred within 18 h of the injury and persisted for at least 3 weeks (Supplementary Fig. 10) . Virtually all ATF3-expressing motoneurons coexpressed CSF1, even 3 weeks after nerve injury ( Fig. 7b and Supplementary Fig. 10) . These results differ greatly from previous reports that found either no change in CSF1 (ref. 40) or an induction of CSF1 in microglia, not neurons 41 , in the facial motor nucleus after VIIth nerve injury. Importantly, we found that the nerve injury-induced ventral horn microglia activation (enhanced Iba1 immunostaining) and microglial engulfment of motoneurons occurred only around motoneuron cell bodies and dendrites in which CSF1 expression increased (Fig. 7d,e ). And just as sensory neuron-derived CSF1 is intraxonally transported ( Fig. 2c  and Supplementary Fig. 2b) , so the induced motoneuronal CSF1 is also transported in axons that exit the spinal cord (Fig. 7e) . Indeed, we observed accumulation of CSF1 at the peripheral nerve injury site (Fig. 7f) . Thus, CSF1 is induced in both injured sensory and motoneurons and is axonally transported to the dorsal horn and to the periphery, respectively.
Ventral horn microglia proliferation is CSF1 dependent
To investigate the consequence of CSF1 induction in injured motoneurons, we crossed Csf1 fl/fl mouse with a Nestin-Cre mouse, in which Cre recombinase is expressed in most CNS neurons 42 . Nerve injuryinduced ATF3 expression in axotomized motoneurons was not affected in these mice, but the CSF1 upregulation in motoneurons was substantially reduced (Fig. 7g) . Only ~30% of ATF3+ motoneurons expressed CSF1 (Fig. 7g) , compared with 100% of ATF3+ motoneurons in wildtype mice (Fig. 7b) . The residual expression of CSF1 in motoneurons presumably reflects incomplete Nestin-Cre-mediated recombination in motoneurons. Notably, preventing CSF1 upregulation in motoneurons largely eliminated the nerve injury-induced microglia activation ( Fig. 7h) and proliferation ( Fig. 7i-k) in the ventral horn. The topographic consequences of neuronal deletion of Csf1 were impressive. Deletion of Csf1 from sensory neurons (Adv-Cre; Fig. 3b ) altered neither motoneuronal CSF1 induction nor ventral horn microglial activation after nerve injury (Fig. 8a,b) . Rather, the reduced nerve injury-induced microglia activation was limited to the dorsal horn, in the terminal field of the injured afferents (Fig. 8a,b) . In contrast, deletion of Csf1 from CNS neurons (Nestin-Cre; Fig. 7g ) markedly reduced nerve injury-induced microglia activation in the ventral horn ( Fig. 8c) . Note that baseline microglial density was also reduced in these mice (Fig. 8a,c) . Despite this overall reduction, the nerve injury-induced CSF1 induction was preserved in sensory neurons in these mice (Supplementary Fig. 11) , as was the dorsal horn microglial activation (Fig. 8c) .
DISCUSSION
Although there is general agreement that microglia are important contributors to the neuropathic pain following peripheral nerve injury, the manner in which injured sensory neurons communicate with There was no effect on ventral horn microglia activation or on motoneuronal CSF1 induction. (c) Csf1 deletion from the majority of CNS neurons (Nestin-Cre; Csf1 fl/fl ) reduced ventral horn microglia activation after injury (see also Fig. 7h ). Note that the density of microglia in the spinal cord contralateral to the nerve injury was reduced in the mutant mice. Despite this overall reduction, microglia were still activated in the dorsal horn ipsilateral to the nerve injury in the mutant mice. Scale bar represents 200 µm. npg a r t I C l e S and activate microglia to produce this pain condition is not known. We found that injured sensory neurons de novo expressed CSF1 and transported it to the spinal cord, where it engaged microglia via an interaction with microglial CSF1R. Via a DAP12-dependent microglial pathway, CSF1 in turn upregulated microglial genes that have been implicated in the neuropathic pain phenotype. Injured neuronderived CSF1 also triggered a DAP12-independent microglia proliferation/self-renewal in the spinal cord.
Injured neuron-derived CSF1, microglia activation and pain Although CSF1 is known for its in vitro colony-stimulating effect on cultured microglia 23 , its in vivo role is much less understood, largely because of limitations of the available in vivo animal models, notably the Csf1 point mutation op/op mouse 43 . Given that this mouse has a substantial deficit in microglia development 24 , it is not ideal for the study of adult microglia functionality 4 . Moreover, because of the global Csf1 mutation in these mice, the contribution of CSF1 from a specific cell type cannot be assessed. Indeed, although it has been reported that nerve injury-induced microglial activation in the facial nucleus is attenuated in op/op mice 44 , another study concluded that the source of the CSF1 triggering the microglial response was microglia 41 , not neurons. Very recent studies used systemic administration of CSF1R inhibitors 45 . However, as the CSF1R has two ligands, CSF1 and IL-34 (ref. 26) , the action of the inhibitor cannot be unequivocally attributed to CSF1 blockade. In addition, the source of relevant CSF1 cannot be determined with this approach.
We found that CSF1 was markedly and selectively induced in injured (ATF3+) sensory neurons after nerve injury and was transported to the spinal cord, where CSF1R was also upregulated. Notably, selective deletion of Csf1 from sensory neurons substantially reduced nerve injury-induced dorsal horn microglial activation and completely prevented the neuropathic pain behavioral phenotype. Furthermore, intrathecal injection of CSF1 produced both mechanical hypersensitivity and microglia activation. Taken together, these results provide, to the best of our knowledge, the first evidence that upregulation of CSF1 in injured neurons is the critical contributor to nerve injuryinduced microglia activation and neuropathic pain.
An important basis for our conclusion as to the essential contribution of sensory neuron-derived CSF1 came from our concurrent demonstration of spinal cord upregulation of microglial CSF1R. In sharp contrast, although CCL21 is reportedly upregulated in the DRG after nerve injury 13 , none of the CCL21 receptors, namely CCR7 and CXCR3 (ref. 46) , was expressed in the dorsal cord, even after peripheral nerve injury (Supplementary Table 1) . In fact, our RNA-Seq analysis could not even confirm the upregulation of CCL21 in the DRG (Supplementary Table 1) . Finally, although it has been suggested that neurons express several membrane proteins (for example, CD200) that inhibit microglia activity and that microglia activation results from downregulation of these inhibitory proteins 47 , we found no change in the expression of their corresponding genes in the DRG after nerve injury (Supplementary Table 1) .
A microglial CSF1R-DAP12 pathway mediates neuropathic pain There are many microglial genes that have been implicated in neuropathic pain, but the microglial signaling pathways through which these genes are induced after nerve injury have yet to be fully defined. We found that the de novo expression of CSF1 in sensory neurons engages a DAP12-dependent pathway. Notably, we found that this CSF1-CSF1R-DAP12 pathway lies upstream of microglial genes that are critical to neuropathic pain development 6, 48, 49 , including CatS, CX3CR1 (Figs. 4e,f and 5e,f) , P2X4, Irf8 and Irf5 (Supplementary Fig. 12) .
Given that DAP12 lies upstream of these genes, it follows that targeting DAP12 should be considered in the pharmacotherapy of neuropathic pain. Notably, although the CSF1-CSF1R-DAP12 pathway lies upstream of P2X4 gene induction, intrathecal CSF1 induced equivalent mechanical hypersensitivity in P2X4 knockout and wild-type mice (Fig. 4d) . We conclude that the initial microglial signaling via CSF1R is P2X4 independent.
Nerve injury induces CSF1-dependent microglia self-renewal Our finding that microglial-specific, rather than monocyte-specific, genes are upregulated in the spinal cord after nerve injury is consistent with a previous report of no significant monocyte infiltration after nerve injury 20 . Although it has been reported that Nestin-expressing microglia progenitor cells contribute to microglia repopulation after pharmacological depletion of microglia 45 , we did not observe Nestin expression in any of the proliferating BrdU+ cells in our model (data not shown). In fact, all of the BrdU+ cells expressed CSF1R (Fig. 6a) , suggesting that expansion of the spinal cord microglia population after nerve injury results from self-renewal of resident microglia.
To the best of our knowledge, however, little is known about the signal that triggers microglia self-renewal in vivo, after peripheral nerve injury or indeed in any neurological condition. We found that CSF1 induced in injured sensory and motoneurons is, in fact, the in vivo signal that transforms the microglia from a resident, homeostatic state into a highly proliferative one. As CSF1R signaling is required for microglia embryonic development 25 , our findings indicate that injuryinduced adult microglia proliferation and self-renewal recapitulates the CSF1R-mediated pathway that is active in embryonic stem cells. However, although DAP12 is required for CSF1-induced proliferation of bone marrow-derived macrophages in vitro 39 , we found that nerve injury-and CSF1-induced microglia proliferation in vivo are DAP12 independent. Clearly, the signal transduction pathway that operates in adult microglia in vivo differs greatly from the pathway that in vitro studies identified from bone marrow-derived macrophages.
CSF1-induced microglial activation and proliferation
Microglia activation after nerve injury is typically concluded from enhanced expression of specific microglia markers, notably CD11b or Iba1, but self-renewal-based proliferation of microglia is also a major manifestation of their activation. We distinguished two biomarkers of microglia activation (Supplementary Fig. 13 ). Within 1 d of nerve injury, before microglia proliferation (BrdU incorporation) occurred, we documented a DAP12-dependent induction of microglial genes, including many implicated in neuropathic pain. Among these genes were Ctss, which encodes CatS, the protease that is released by activated microglia to cleave fractalkine from neuronal membrane 8 , and Bdnf, which is reported to be released from microglia, resulting in a shift of the anion gradient of pain transmission neurons 33 . This shift reduces GABAergic inhibitory control, which contributes to the ensuing hyperexcitability 50 . Only at 2 d after nerve injury did we detect the BrdU marker of microglial proliferation. Unlike microglial gene upregulation, however, neither nerve injury-nor CSF1-induced microglia proliferation is DAP12 dependent. We conclude that the de novo expression of CSF1 after injury engages two distinct microglial processes, a DAP12-dependent pathway for microglia gene upregulation and the consequent neuropathic pain, and a DAP12independent pathway for microglia proliferation/self-renewal. Given that the DAP12-dependent pathway is presumably also engaged by the newly generated microglia, we suggest that interfering with this pathway will reduce both the resident and proliferating microglia contribution to the neuropathic pain phenotype. npg a r t I C l e S METhODS Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper. was assumed to be normal and variances were assumed to be equal across groups, but this was not formally tested. In all the behavior studies, the animals were randomly assigned to test cylinders, with the person who performed the behavioral test blind to the animal assignment.
A Supplementary methods checklist is available.
